文献速递重症综合管理与镇静镇痛心脑血管急症

神经重症监护中的谵妄:通过毛发分析揭示未披露的精神药物使用与应激暴露

Delirium in Neurocritical Care: Uncovering Undisclosed Psychotropic Substance and Medication Use and Stress Exposure by Hair Analysis.
PubMed 文献 · Neurocrit Care · 2024-07-16
一句话结论神经重症患者毛发分析显示,未披露的抗抑郁药/抗精神病药使用及慢性酒精消耗与谵妄相关,内源性大麻素水平亦与谵妄独立相关。

该研究连续纳入神经重症监护病房的急性脑损伤成人患者,用ICU意识模糊评估法(CAM-ICU)诊断谵妄,并用液相色谱-串联质谱法检测毛发中的精神活性物质、药物、乙基葡萄糖醛酸苷、类固醇激素和内源性大麻素。50例患者中21例(42%)发生谵妄;谵妄组毛发中抗抑郁药(43% vs 14%,p=0.040)和抗精神病药(29% vs 0%,p=0.021)检出率更高,乙基葡萄糖醛酸苷水平更高(p=0.049),花生四烯酸乙醇胺(AEA)浓度更高(p=0.005),而油酰乙醇胺(p=0.045)和棕榈酰乙醇胺(PEA)(p=0.017)浓度更低。向后逐步逻辑回归显示抗抑郁药和AEA/PEA是谵妄的独立相关预测因素。作者认为毛发分析可提供关于慢性应激和精神药物使用的关键信息,未披露的抗抑郁药/抗精神病药使用或强烈慢性酒精消耗可能可治疗(继续用药或酒精情况下给予低剂量苯二氮䓬类),慢性应激可通过毛发应激标志物和内源性大麻素评估,可能实现个体化谵妄风险分层和预防措施。

要点

  • 在50例连续纳入的神经重症急性脑损伤成人患者中,42%(21例)被CAM-ICU诊断为谵妄。
  • 谵妄组毛发抗抑郁药检出率43% vs 非谵妄组14%(p=0.040),抗精神病药29% vs 0%(p=0.021)。
  • 谵妄组毛发乙基葡萄糖醛酸苷水平更高(p=0.049),提示慢性酒精消耗与谵妄相关。
  • 谵妄组AEA浓度更高(p=0.005),油酰乙醇胺(p=0.045)和PEA(p=0.017)浓度更低;抗抑郁药和AEA/PEA是独立相关预测因素。
  • 作者认为毛发分析可揭示未披露的精神药物使用和慢性应激,可能有助于个体化谵妄风险分层和预防。

适用人群与场景

  • 连续纳入的神经重症监护病房急性脑损伤成人患者。

诊断标准与关键阈值

  • 谵妄诊断使用ICU意识模糊评估法(Confusion Assessment Method for the Intensive Care Unit)。

处置流程与药物剂量

  • 作者认为,未披露的抗抑郁药/抗精神病药使用或强烈慢性酒精消耗可能可治疗:继续用药,或在酒精情况下给予低剂量苯二氮䓬类。

研究设计与关键结果

  • 研究类型为连续纳入的观察性研究,样本量50例,人群为神经重症监护病房急性脑损伤成人患者,21例(42%)诊断为谵妄。
  • 谵妄组毛发抗抑郁药检出率43% vs 非谵妄组14%(p=0.040);抗精神病药检出率29% vs 0%(p=0.021)。
  • 谵妄组乙基葡萄糖醛酸苷水平更高(p=0.049)。
  • 谵妄组AEA浓度更高(p=0.005),油酰乙醇胺浓度更低(p=0.045),PEA浓度更低(p=0.017)。
  • 向后逐步逻辑回归分析显示,抗抑郁药和AEA/PEA是谵妄的独立相关预测因素。

证据类型、等级与局限

  • 证据类型:观察性研究(连续纳入的成人患者)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,毛发分析可提供关于慢性应激和精神药物使用的关键且否则无法获得的信息。
  • 作者认为,未披露的抗抑郁药/抗精神病药使用或强烈慢性酒精消耗可能可治疗:继续用药,或在酒精情况下给予低剂量苯二氮䓬类。
  • 作者认为,慢性应激可通过毛发应激标志物和内源性大麻素评估,可能实现个体化谵妄风险分层和预防措施。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: In intensive care, delirium is frequent, prolongs the stay, increases health care costs, and worsens patient outcome. Several substances and medications as well as stress can impact the risk of delirium; however, assessment of previous exposure to psychotropic agents and stress by self-reports or third-party information is not always reliable. Hair analysis can be used to objectively assess medication and substance use (including chronic alcohol consumption), and allows for the determination of stress-related long-term changes in steroid hormones and endocannabinoids.

METHODS: Consecutive adult patients with acute brain injury admitted to the neurocritical care unit were included. Delirium was diagnosed using the Confusion Assessment Method for the Intensive Care Unit. Liquid chromatography coupled with tandem mass spectrometry was used to investigate psychoactive substances and medications, ethyl glucuronide, steroid hormones, and endocannabinoids in hair samples. Univariable and multivariable analyses were used to reveal any associations with the occurrence of delirium.

RESULTS: Of 50 consecutive patients, 21 (42%) were diagnosed with delirium. Detection of antipsychotics or antidepressants in hair was more frequent in patients with delirium (antidepressants: 43% vs. 14%, p = 0.040; antipsychotics: 29% vs. 0%, p = 0.021). These patients also displayed higher ethyl glucuronide levels (p = 0.049). Anandamide (AEA) concentrations were higher in patients with delirium (p = 0.005), whereas oleoylethanolamide (p = 0.045) and palmitoylethanolamide (PEA) (p = 0.017) concentrations were lower in patients with delirium. Backward stepwise logistic regression analysis revealed antidepressants and AEA/PEA to be independent relevant predictors of delirium.

CONCLUSIONS: Hair analysis provides crucial and otherwise unattainable information regarding chronic stress and the use of psychotropic substances and medications. Undisclosed antidepressant/antipsychotic use or intense chronic alcohol consumption is susceptible to treatment (continuation of medication or provision of low-dose benzodiazepines in case of alcohol). Chronic stress can be evaluated using stress markers and endocannabinoids in hair, potentially allowing for personalized delirium risk stratification and preventive measures.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Bögli SY, Capone C, Baumgartner MR, et al. Delirium in Neurocritical Care: Uncovering Undisclosed Psychotropic Substance and Medication Use and Stress Exposure by Hair Analysis. Neurocrit Care. 2024. PMID: 39009940. doi:10.1007/s12028-024-02052-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。